Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Insulin Stories

2013-09-25 23:31:41

On Wednesday September 25th, SimplyRAC (“Simply Rent a Car”) announced that it will donate 3% of time and mileage proceeds to JDRF when customers mention the organization, the leading global funder of type 1 diabetes (T1D) research. Los Angeles, CA (PRWEB) September 25, 2013 SimplyRAC, Los Angeles’ premier car rental service today announced their support of JDRF to drive up funds to help find a cure for type 1 diabetes. As a show of support for JDRF, SimplyRAC will donate 3% of all...

2013-09-24 12:28:48

NEW YORK and Santa Barbara, Calif., Sept. 24, 2013 /PRNewswire-USNewswire/ -- JDRF, Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) are pleased to announce the first successful clinical research trial using the artificial pancreas in conjunction with ultra-rapid-acting inhaled insulin. This represents a groundbreaking potential advancement in the treatment of type 1 diabetes (T1D). It establishes that the disease can...

2013-09-24 09:42:06

A new study by a team of University of Notre Dame researchers, which appears in the Sept. 2 edition of the journal PLoS ONE, is a significant step in understanding the molecular genetic and physiological basis for a spectrum of metabolic diseases related to circadian function. Obesity and diabetes have reached epidemic levels and are responsible for increased morbidity and mortality throughout the world. Furthermore, the incidence of metabolic disease is significantly elevated in...

2013-09-24 08:29:58

- Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin - PARIS, Sept. 24, 2013 /PRNewswire/ -- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today new GetGoal-L sub-analysis results showing that reductions in HbA(1c) with Lyxumia(®) (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose (FPG). These findings are consistent with the...

2013-09-24 08:29:46

Two pooled analyses of data from clinical trials in adults with type 2 diabetes, including the elderly with normal renal function to severe renal impairment, found similar incidence of adverse events for linagliptin compared with placebo RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 24, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (Lilly; NYSE: LLY) today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the...

2013-09-23 10:22:14

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology. Alefacept, an engineered fusion protein targeting a surface molecule, CD2, found on T-lymphocytes, was the first...

2013-09-18 23:22:38

The global market for insulin drug and delivery devices was valued at $24 billion in 2012 and is expected to reach $25.7 billion by 2013. BCC Research projects the market to reach nearly $40.2 billion by 2018 and register a compound annual growth rate (CAGR) of 9.3%. Wellesley, MA (PRWEB) September 18, 2013 According to a new technical market research report, Global Markets for Emerging Insulin Drug and Delivery Technologies from BCC Research (http://www.bccresearch.com), the global...

2013-09-17 12:28:19

ABBOTT PARK, Ill., Sept. 17, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System((TM)). The new icon-driven system provides sleek design, visual glucose trend indicators and insulin logging - all delivered in a single device to support daily diabetes management. According to the World Health Organization, the prevalence of diabetes is increasing in the...

2013-09-17 08:31:30

Industry-leading team assembled to accelerate clinical development of the biotechnology company's dendritic cell therapy for Type 1 diabetes EDGEWATER, N.J., Sept. 17, 2013 /PRNewswire/ -- DiaVacs, Inc., a clinical stage biotechnology company focused on the goal of curing autoimmune diseases, with its first indication being Type 1 diabetes mellitus (T1DM), today announced that it has appointed Orville Kolterman, MD, as Chief Medical Officer. In this role, Dr. Kolterman will assume...

2013-09-17 08:31:21

Presentations at EASD to include safety and efficacy data for the Diabetes Alliance compounds RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (Lilly; NYSE: LLY) today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin(^) at the 49(th) Annual Meeting of the European Association for the Study of Diabetes (EASD), which will take place in Barcelona from...


Latest Insulin Reference Libraries

Pancreas
2013-01-02 11:22:15

The pancreas is a digestive and an endocrine organ with both endocrine and exocrine functions. It is about six inches long located in the upper portion of the abdominal cavity. The head of the pancreas lies within the indentation of the duodenum and is connected to it by the pancreatic duct. The uncinate process extends from the head and the neck connects to the body of the pancreas, which lies directly behind the stomach. The tail of the pancreas extends to the left side of the body and is...

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (2 articles) »